Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621023 · ClinicalTrials.gov registry record · Phase 2
Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00621023 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 7 participants.
The verdict
NCT00621023, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This will be an open-label, non-randomized trial pilot phase II trial open to patients with myelodysplastic syndrome. The purpose of the study is to find out if the combination of decitabine, arsenic trioxide and ascorbic acid is safe.
Interventions
- DRUG Decitabine, Arsenic Trioxide and Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00621023
The ClinicalTrials.gov registry entry for NCT00621023 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Decitabine, Arsenic Trioxide and Ascorbic Acid is the first listed.
NCT00621023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00621023 about?
NCT00621023 is a clinical study titled "Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome". This will be an open-label, non-randomized trial pilot phase II trial open to patients with myelodysplastic syndrome. The purpose of the study is to find out if the combination of decitabine, arsenic trioxide and ascorbic acid is safe.
What is the current status of trial NCT00621023?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-11. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00621023?
The interventions under investigation include: Decitabine, Arsenic Trioxide and Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT00621023?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.